Stock CADL CANDEL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
10.58 USD -13.77% Intraday chart for Candel Therapeutics, Inc. -24.43% +619.73%
Apr. 11 Sector Update: Health Care Stocks Decline Thursday Afternoon MT
Apr. 11 Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug MT

Business Summary

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.

Number of employees: 42

Managers

Managers TitleAgeSince
Paul-Peter Tak CEO
 Chief Executive Officer 64 20-08-31
Estuardo Aguilar-Cordova FOU
 Founder 66 01-12-31
Charles Schoch DFI
 Director of Finance/CFO 39 -
Seshu Tyagarajan CTO
 Chief Tech/Sci/R&D Officer 57 22-03-01
Francesca Barone CTO
 Chief Tech/Sci/R&D Officer 47 20-10-31
William Nichols CTO
 Chief Tech/Sci/R&D Officer 55 22-09-11
Ileen B. Winick HRO
 Human Resources Officer - 20-12-31
Nathan Caffo PRN
 Corporate Officer/Principal 55 20-08-31
Susan Stewart LAW
 General Counsel 64 20-09-30

Members of the board

Members of the board TitleAgeSince
Joseph Papa BRD
 Director/Board Member 68 22-08-07
Edward Benz BRD
 Director/Board Member 78 17-08-31
Paul Manning CHM
 Chairman 68 18-10-31
Gary Nabel BRD
 Director/Board Member 70 22-08-07
Estuardo Aguilar-Cordova FOU
 Founder 66 01-12-31
Paul-Peter Tak CEO
 Chief Executive Officer 64 20-08-31
Renee Gaeta BRD
 Director/Board Member 42 22-08-07
Diem Nguyen BRD
 Director/Board Member 52 21-07-14
Christopher Martell BRD
 Director/Board Member 45 18-10-31
Nicoletta Loggia BRD
 Director/Board Member - 23-06-06

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 29,867,339 20,005,186 ( 66.98 %) 122,608 ( 0.4105 %) 66.98 %

Shareholders

NameEquities%Valuation
Estuardo Aguilar-Cordova
10.75 %
3,153,815 10.75 % 22 M $
Laura Aguilar
10.33 %
3,032,700 10.33 % 21 M $
Paul Manning
9.804 %
2,877,158 9.804 % 20 M $
Northpond Ventures LLC
6.594 %
1,935,215 6.594 % 14 M $
Sands Capital Ventures LLC
2.766 %
811,737 2.766 % 6 M $
Vanguard Group, Inc. (Subfiler)
1.844 %
541,295 1.844 % 4 M $
Christopher Martell
1.484 %
435,514 1.484 % 3 M $
Banor Capital Ltd.
1.359 %
398,826 1.359 % 3 M $
Geode Capital Management LLC
0.4965 %
145,706 0.4965 % 1 M $
Paul-Peter Tak
0.3254 %
95,495 0.3254 % 673 240 $

Company contact information

Candel Therapeutics, Inc.

117 Kendrick Street Suite 450

02494, Needham

+

http://www.candeltx.com
address Candel Therapeutics, Inc.(CADL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
10.58 USD
Average target price
11 USD
Spread / Average Target
+3.97%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CANDEL THERAPEUTICS, INC. Stock Candel Therapeutics, Inc.
+619.73% 310M
MODERNA, INC. Stock Moderna, Inc.
+64.23% 62.59B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.31% 41.18B
LONZA GROUP AG Stock Lonza Group AG
+44.70% 40.29B
CELLTRION, INC. Stock Celltrion, Inc.
-8.29% 27.9B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.97% 26.21B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.16% 19.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+7.54% 13.08B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.17% 12.05B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.72% 12.26B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CADL Stock
  4. Company Candel Therapeutics, Inc.